Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of Rapamycin in LS174T colon cancer cells by Benoit, M.
Université de Lausanne - Faculté de Biologie et de Médecine 
Département des services de chirurgie et d'anesthésiologie 
Service de chirurgie viscérale 
Targeting the JNK signaling pathway potentiates the 
antiproliferative efficacy of Rapamycin in LS17 4T colon 
cancer cells. 
THESE 
préparée sous la direction du Professeur Nicolas Demartines MD 
avec la collaboration du Docteur Olivier Dormond MD-PhD 
et présentée à la faculté de biologie et médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
8 r 1 
par 
Michael BENOIT 
Médecin diplômé de la Confédération Suisse 
Originaire de La Sagne et Les-Ponts-de-Martel, Neuchâtel, Suisse 
Lausanne 
2011 
Bibliothèque Un1versita11 ~ 
de Médecine/ BiUM 
CHUV-BH08 - Bugnon 46 
CH-îOî 1 Lausanne 
~IL 1 Université de Lausanne 
Ecole Doctorale 
Doctorat en médecine 
Imprimatur 
Vu le rapport présenté par le jury d'examen, con1posé de 
Directeur de thèse 
Co-Directeur de thèse 
Monsieur le Professeur Nicolas Demartines 
Expert Monsieur le Professeur Curzio Rüegg 
Directrice de l'Ecole Madame le Professeur Stephanie Clarice 
doctorale 
la Comn1ission MD de l'Ecole doctorale autorise l1in1pression de la thèse de 
Monsieur Michael Benoit 
intitulée 
Targeting the /NI< signaling pathway potentiates the 
antiproliferative efficacy of Rapamycin in LS174T colon 
cancer cells 
Lausanne, le 30 novembre 2011 
pour Le Doyen 
de la Faculté de Biologie et de Médecine 
s:::~ 
Madmne le Professeur Stephanie Clarke 
Directrice de l'Ecole doctorale 
Résumé 
Les récentes thérapies anticancéreuses développées visent principalement 
à inhiber les protéines mutées et responsables de la croissance des 
cellules cancéreuses. Dans ce contexte, l'inhibition d'une protéine appelée 
mTOR est une stratégie prometteuse. En effet, mTOR régule la prolifération 
et la survie cellulaire et mTOR est fréquemment activé dans les cellules 
tumorales. 
De nombreuses études ont démontré l'efficacité anti-tumorale d'inhibiteurs 
de mTOR telle que la rapamycine aussi bien dans des modèles 
expérimentaux que chez les patients souffrant de cancers. Ces études ont 
cependant également démontré que l'inhibition de mTOR induit l'activation 
d'autres protéines cellulaires qui vont induire la prolifération cellulaire et 
ainsi limiter l'effet anti-tumoral des inhibiteurs de mTOR. En particulier, la 
rapamycine induit l'activation de la voie de signalisation Pl3K/Akt qui joue 
un rôle prépondérant dans la croissance cellulaire. 
Dans ce travail, nous avons étudié l'effet de la rapamycine sur une protéine 
appelée JNK ainsi que le rôle de JNK sur les effets anti-tumoraux de la 
rapamycine. JNK est une protéine impliquée dans la survie et la 
prolifération cellulaire. Elle est activée notamment par la voie de 
signalisation Pl3K/Akt. De ce fait, nous avons émis l'hypothèse que la 
rapamycine induirait l'activation de JNK, réduisant ainsi l'efficacité anti-
tumorale de la rapamycine. En utilisant une lignée cellulaire tumorale 
(LS 17 4T) dérivée du cancer colorectal, nous avons observé que la 
rapamycine induisait l'activation de JNK. Nous avons également observé 
que l'inhibition de JNK par le SP600125, un inhibiteur chimique de JNK, ou 
par la surexpression d'un dominant négatif de JNK dans les cellules 
LS17 4T potentialisait l'effet anti-tumoral de la rapamycine in vitro ainsi que 
dans un modèle murin de xénogreffe tumorale in vivo. 
En conclusion, nous avons observé que l'activation de JNK induite par la 
rapamycine entraine une réduction de l'effet anti-tumoral de cette dernière. 
Nous proposons ainsi que l'inhibition simultanée de JNK et de mTOR 
représente une nouvelle option thérapeutique en oncologie qu'il conviendra 
de confirmer dans d'autres modèles expérimentaux avant d'être testée 
dans des études cliniques. 
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Bachground. Targeting the mTOR signaling path-
way with rapamycin in cancer therapy has been less 
successful than expected due in part to the removal 
of a negative feedback loop resulting in the over-
activation of the PI3K/Akt signaling pathway. As the 
c-Jun N-terminal kinase (JNK) signaling pathway 
has been found to be a functional target of PI3K, we in-
vesti gate the role of JNK in the anticancer efficacy of 
rapamycin. 
Materials and Metlwds. The colon cancer cell line 
LS174T was treated with mpamycin and JNK phos-
phorylation was analyzed by Western Blot. Overex-
pression of a constitutively negative mutant of JNK 
in LSl 74T cells or treatment of LSl 74T cells with the 
JNI{ inhibitor SP600125 were used to determine 
the role of JNK in rapamycin-mediated tumor growth 
inhibition. 
Results. Treatment ofLS174T cells with rapamycin 
resulted in the phosphorylation of JNK as observed 
by Western Blot. The expression of a negative mutant 
of JNK in LSl 74T cells or ti·eatment of LSl 74T cells 
with SP600125 enhanced the antiproliferative effects 
ofrapamycin. In addition, in vivo, the antitumor activ-
ity of rapamycin was potentiated on LSl 74T tumor xe-
nografts that expressed the dominant negative mutant 
ofJNK. 
Conclusions. Taken together, these results show 
that rapamycin-induced JNK phospl10rylation and ac-
tivation reduces the antitumor efficacy of rapamycin 
in LSl 7 4T cells. © 2011 Elsevier lue. All rights reserved. 
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tumor; signaling. 
1 To whom coITespondence and reprint requests should be ad-
dressedatDepartment ofVisceral Surgery, Pavillon 3, CHUV, Avenue 
de Beaumont, 1011 Lausanne, Switzerland. E-mail: olivier.dormond@ 
chuv.ch. 
INTRODUCTION 
The mammalian tai·get of rapamycin (mTOR) is 
a highly conserved ser/thr kinase that plays a key role 
in cell growth, proliferation and survival. mTOR 
regulates cell growth in response to growth factors, nu-
trients and energy [1]. mTOR is present in two func-
tionally distinct complexes, mTORCl and mTORC2. 
mTORCl consists of mTOR, rapto1', deptor, PRAS40, 
and mLST8. mTORC2 is composed of mTOR, rictor, 
sinl, mLST8, deptor, and protor [2]. While acute expo-
sme to rapamycin blocks mTORCl, it does not affect 
mTORC2 [3]. Despite several experimental evidences 
in different animal models that the inhibition of 
mTORCl by rapamycin and its analogs blocks tmnor 
progression, its benefits in clinical trials have been 
less successful than expected [ 4, 5]. Pai·t of it might be 
explained by the observation that the inhibition of 
mTORCl results in the activation of the PI3K/Akt sig-
naling pathway, which induces signals that sustain 
proliferation and survival and, thus, counteract the 
anti-cancer efficacy ofrapamycin [6]. 
Jun N-terminal kinases (JNKs), also known as 
stress-activated MAP kinases (SAPK), belong to the 
family of MAP kinases that regulate cell differentia-
tion, proliferation, and apoptosis. The JNK protein ld-
nases are encoded by three genes. While JNKl and 
JNK 2 ai·e ubiquitously expressed, JNK3 expression is 
limited to brain, heart, and testis [7, 8]. Although sev-
ei·al reports have unravelled the critical role of JNK 
in inducing apoptosis, several evidences have also dem-
onstrated a role of JNK in cancer development by en-
hancing cell proliferation and survival [7-10]. Indeed, 
the requirement of JNK in the development of various 
cancern jncluding colon, ovar.ian as well as prostate 
cancer has been suggested [11-14). Interestingly, 
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constitutively active alleles of PI3K or activation of 
PI3K.following PTEN loss activate JNK resulting in 
cell transformation [15, 16]. 
Several studies have demonstrated that rapamycin 
induces the activation of proliferative and prosurvival 
effectors such as PI3K, which limits its anticancer effi-
cacy. Since JNK is a functional target of PI3K, we want 
here to determine the effect of rapamycin on JNK sig-
naling pathway and to explore the anticancer efficacy 
of the simultaneous inhibition ofmTOR and JNK. 
MATERIALS AND METHODS 
Cell Lines, Antiboclies, and Reagents 
The LSl 7 4T colon cancer cell line was purchased from the Ameri-
can Type Culture Collection (ATCC, Molsheim, füance) and cultured 
in Dulbecco's modified Eagle's medium containing 10% fetal calf se-
rum. Rapamycin was obtained from LC Laboratories (Woburn, MA). 
Antibodies directed against phospho-Akt (8473), Akt, phospho JNK 
(Thr 183/Tyr 185), JNK, phospho-S6 ribosomal protein (Ser 235/ 
236), and S6 ribosomal protein were from Cell Signaling Technology 
(Danvers, MA). Antibody to FLAG was obtained from Sigma 
(Sigma-Aldrich, Buchs, Switzerland). The dominant negative mutant 
JNKl (plasmid 13846) and pcDNA3 (plasmid 10792) were obtained 
from Addgene (Cambridge, MA) [17]. 
Cell Transfection 
LSl 7 4T cells were transfeded with pcDNA3 or a flag tagged domi-
nant negative mutant of JNKl using the Effect.ene transfedion 
reagent (Qiagen, Basel, Switzerland) and following the manufac-
turer's instructions. Stable transfectants were selected for resistance 
to G418 (500 µglmL) for 2 wk and further expanded in the presence of 
G418 (100 µg/mL). 
Western Blot Analysis 
LSl 7 4T cells were treated with rapamycin (10 ng/mL) for 30 min, 
1 or 24 h or dimethylsulfoxide (DMSO) as a contrai. Cells were lysed 
in RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 150 ml\1 
NaCl,1% Nonidet P-40, 0.5% sodium deoxycholate, 1% SDS, 5 mM 
EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/mL leupeptin, 
and 1 mM sodium orthovanadate. Protein concentrations were deter-
mined using BCA A<Jsay (Pierce, Rockford, IL). Twenty µg ofproteins 
were separated on 4%-12% polyacrylamide gel and subsequently 
transferred to a polyvinylidene difluoride membrane (Millipore, 
Zug, Switzerland). Membranes were blocked with Odyssey blocking 
buffer (LI-COR Biosciences, Lincoln, NE) and immunoblotted with 
primary antibodies followed by infrared secondary antibodies. Bands 
from immunoreactive proteins were visualized by an Odyssey 
infrared imaging system. 
MTS Proliferation Assay 
MTS proliferation studies were carried out using the CellTiter 96 
Aqueous One Solution (Promega, Dübendorf, Switzerland). LS174T 
cells were plated on 96 well plates and cultured in DMEM 10% 
FES. Twenty-four hours later cells were treated with rapamycin 
(10 ng/mL), SP600125 (10 µM) a combination of both drugs and 
DMSO. Forty-eight hours later, proliferation was monitored with 
the colorimetric assay by measuring the absorbance at 490 nm. Re-
sults are expressed as the mean absorbance ± SD of one representa-
tive expeiiment carried out in triplicate. 
Cell Proliferation Stuclies 
LSl 74T cells were plated in 6-well culture plates at a density of 
200,000 cellsfwell and cultured in DMEM supplemented with 10% fe-
tal calf serum. Twelve hours la ter, cells were treated with rapamycin 
(10 ng/mL) SP600125 (10 pM) a combination ofboth drugs or DMSO 
as a control and incubated for 3, 5 or 7 days. Cells were subsequently 
collected and trypan-blue negative cells were count.ed by light micros-
copy using a Neubauer hemocytorneter. 
Apoptosis Assay 
LSl 74T cells were plated on 96 well plates and cultured in 
DMEM 10% FES. Twenty-fom hours later, cells were treated with 
rapamycin (10 ng/mL), SP600125 (10 µM) a combination of both 
drugs and DMSO for 48 h. Subsequently, cells were harvested and 
apoptosis was monitored using the Cell Detection ELISA Plus 
(Roche Diagnostics, Rotkreuz, Switzerland) following the mannfac-
turer's instructions. 
Tumor Xenografts 
Animal experiments were in accordance with the Swiss Federal An-
imal Regulaiions and approved by the local veterinnry office. Female 
nude mice aged 8 wk were purchased from Charles River (Charles 
River Laborato1ies, St. Germain sur !'Arbresle, France). One million 
LS174T cells or LS174T cells stably transfected with pcDNA3 or 
a dominant negative mutant of JNK were injected subcutaneously 
(s.c.) into the flank ofnude mice. Once the tumor xenografts reached 
100 mm3, mice were randomized into different groups (11 = 5/group) 
and treated 'vith vehicle (ethanol) or rapamycin (1.5 mg/kg/d) for 
20 d. All mi ce were sacrificed after 20 d oftrnatment. Tumor volumes 
were measm·ed using callipers every day and calculated with the 
formula V= rr/(6a2b) where a is the short axis and b the long axis of 
the tumor. 
Statistical Analysis 
Data were analyzecl by Student's t-test or one way ANOV A. Values 
of P < 0.05 were considered statistically significant. 
RESULTS 
Rapamycin Inneases the Phosphorylation of JNK in 
LS174T CeUs 
To determine whether rapamycin induces the activa-
tion of JNK, LS174T colon cancer cells were treated 
v;rith increasing concentrations of rapamycin and JNK 
phosphorylation was determined by Western Blot anal-
ysis as a read-out of JNK activity. We found that treat-
ment of LS174T cells with 10 ng/mL of rapamycin 
increased JNK phosphorylation (Fig. 1A). At this con-
centration, rapamycin also totally blocked mTORCl ac-
tivity as assessed by the dephosphorylation of 86 
ribosomal protein, a dovmstream effector of mTORCl. 
A lower dose of rapamycin (1 ng/mL) had no effect on 
JNK phosphorylation and did not block mTORCl 
(Fig. 1A). The effect of rapamycin on JNK phosphoryla-
tion was apparent after 30 min and persisted for 24 h 
(Fig.1B). In addition, treatment ofLSl 7 4T cells with ra-
pamycin increased Akt phosphorylation, consistent 
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FIG. 1. Rapamycin increases JNK phosphorylation in LS174T 
cells. (A) L817 4T colon cancer cells were treated with increasing con-
centrations of rapamycin for 1 h or DM80 as a control. Cel! lysates 
were analyzed by Western Blot for p110spho-JNK (Thr 183/l'yr 185), 
JNK, phospho-86 ribosorna1 protein (Ser 2351236), and S6 ribosornal 
protein. (B) LS174T colon cancer cells were h·eatecl with rapamycin 
(10 ng/rnL) or DMSO as a control for the indicated tirnes. Cell lysates 
were analyzed by Western Blot for phospho-JNK (Thr 183/l'yr 185), 
JNK, phospho-86 iibosornal protein (Ser 235/236), 86 ribosomal pro-
tein, phospho Akt (Ser 473), and Akt. The illustrated blots are repre-
sentative ofthree similar experirnents. 
with the rnmoval of a negative feedback loop whereby 
the inhibition of mTORCl and its downstream sub-
strate S6Kl results in the activation of the PI3K/Akt 
signaling pathway (Fig.lB) (6). Taken together, these 
results show that rapamycin induces the phosphoryla-
tion ofJNK 
SP600125 Potentiates the Antiproliferative Efficacy of 
Rapamycin 
We next investigated whether rapamycin-mediated 
JNK activation reduces the antiproliferative efficacy 
ofrapamycininLSl 74T cells. Totestthis, LS174Tcells 
were treated with the JNK inhibitor SP600125, rapa-
mycin, a combination ofboth or left untreated and cell 
proliferation was analyzed by MTS assay after 48 h of 
treatment. In preliminary ex:periments, we observed 
that 10 µM ofSP600125 was needed to blockJNK activ-
ity in LSl 74T cells (data not shown). Both rapamycin 
and SP600125 reduced cell proliferation when used as 
a single agent (Fig. 2A). However the combination of 
both had an additive effect that was statistically signif-
icant compared with the single treatments. Consistent 
with this finding, we also found that rapamycin or 
SP600125 reduced LS174T cell number after 3, 6, and 
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FIG. 2. The inhibition of JNK with SP600125 increases the anti-
proliferative effect of rapamycin in LSl 74T cells. (A) LSl 74T cells 
were treated with raparnycin (rapa, 10 ng/rnL) or SP600125 (SP, 
10 µM) alone or a combination of both drugs for 48 h. Proliferation 
was monitored by an MTS assay. Results are expressed as the mean 
absorbance at 490 nrn ± SD of one Tepresentative experirnent carried 
out in tiip1icate. P values were calculated by using a Student's t-test. 
*P < 0.005 compared with control. (B) LSl 74Tcellswere processed as 
under (A). Subsequently, cells were collected after 3, 6, or 9 days of 
treatment and trypan blue negative cells were counted by light mi-
croscopy using aNeubauer hemocytorneter. Mean cell counts ofthree 
independent experirnents were expressed in arbitrary nnits ± SD. 
*P < 0.05 compared with control or as specified by brackets (Student's 
t-test). (C) LS174T cell were processed as under (A). Cells were har-
vested and apoptosis Wllil determined by DNAfragmentation. Results 
are represented as the mean absorbance at 405 nm ± SD (n = 3). 
9 d of treatment (Fig. 2B). This reduction was also 
more significant when rapamycin was used in combina-
tion with SP600125 cornpared to either drug alone. Fi-
nally the effect of rapamycin and SP600125 on 
LS174T cell apoptosis was monitored by quantifying 
DNA fragmentation. Rapamycin and SP600125 either 
as single agent or in combination did not induce cell ap-
optosis (Fig. 2C). 
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The Antiproliferative Efficacy of Rapamycin îs Enhanced 
by the fuq>ression of a Dominant Negative Mutant of JNK in 
LS174T Cells 
To further explore the role of JNK in the antiprolifer-
ative e:fficacy of rapamycin, we stably transfected 
L8174T cells with a dominant negative mutant of 
JNK1 (DN-JNK) or an empty vector as a control 
(pcDNA3) [17). The expression of the dominant nega-
tive mutant of JNKl was confinned by Western blot 
analysis using an anti-flag as well as an anti-JNK anti-
body (Fig. 3A). We found that the expression of 
DN-JNK in LSl 7 4 T cells decreased cell proliferation 
compared with pcDNA3 transfected cells. Further-
roore, the antiprolifürative e:fficacy of rapan1ycin was 
greater on DN-JNK transfected cells compared with 
cells transfected with pcDNA3 (Fig. 3B). Finally, simi-
lar to what we found with SP600125 (Fig. 2C), the ex-
pression ofDN-JNK did not induce cell apoptosis even 
in the presence ofrapamycin (Fig. 3C). 
The Anticancer Efficacy of Rapamycin is Enhanced in 
LSI 74T Tumor Xenografts that Express a Dominant Negative 
Mutant of JNK 
We next evaluated the relevance of rapamycin-
mediated JNK activation on the antitumor ef-ficacy of 
rapamycin in vivo. We first determined whether rapa-
mycin increased JNK phosphorylation in LS174T 
tumor xenogrnfts. LS174T cells were injected subcuta-
neously into immunodeficient mice that were subse-
quently treated with rapamycin or not. Western 
Blot analysis of the tumor lysates revealed that 
rapamycin increased the phosphorylation of JNK 
(Fig. 4A). We further analyzed whether rapamycin-
mediated JNK activation counteracts the gmwth inhib-
itory effects of rapamycin. To test this, LS174T cells 
that were stably transected with DN-JNK or pcDNA3 
were injected into nude mice. We observed that the 
growth of the xenografts expressing the dominant neg-
ative mutant of JNK was rcduced. Moreover, we found 
that the antitumor efficacy of rapamycin was potenti-
ated in tumor xenografts expressing the dominant neg-
ative mutant of JNK (Fig. 4B). Talrnn together, these 
results suggest that rapamycin-mediated JNK activa-
tion reduces the antitumor efficacy ofrapamycin. 
DISCUSSION 
In this report, we have found that the treatment of 
LSl 7 4T cells with rapamycin induced the phosphoryla-
tion of JNK and that the expression of a dominant neg-
ative mutant of JNK or the exposure of LS174T cells 
to SP600125 potentiated rapamycin growth inhibitory 
effects. 
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FIG. 3. The expression of a dominant negative mutant of JNK in 
LSl 74Tcells enhances the antîproliferative efficacyofrapamycin. (A) 
LSl 7 4T cells were sl.ably transfected with an empty vector (pcDNA3) 
or a dominant negative mutant of JNK (DN-JNK). Cells were lysed 
and analyzed by Western blot for DN-JNK using an anti-ftag and an 
anti..JNIC antîbody. Actin was used as a loading control. (B) LSl 74T 
cells were stably transfected with a dominant negative mutant of 
JNK or pcDNA3 as a contrnl were treated with rapamycin (Rapa, 
10 ng/mL) for 72 h. Cells were subsequently collected and trypan 
bluenegative cells were counted by Hght nricroscopyusing a Neubauer 
hemocytometer. Results are Hlustrated as the mean cell count ofthree 
representative experiments ± SD. *P < 0.005 compared with control 
(Student's t-test). (C) LSl 74Twere processed as un der (B). Apoptosis 
was determined by DNA fragmentation and are expressed as the 
mean absorbance at 405 nrn ± SD (11 = 3). 
Experimental studies and clinical trials have shown 
that the blockade of one molecular target in cancer ther-
apy results in limited benefits [18, 19]. Therefore, opti-
mal therapeutic approaches involve the inhibition of 
multiple molecular targets. Consistent with this 
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FIG. 4. The expression of a dominant negative mutant of ,JNK in 
LS174T xenografts potentiates the anticanccr efficacy ofrapamycin. 
(A) LS174T cells were injected into nude mice. Once the tumor 
reached 100 mm3, mice were treated with vehicle or rapamycin (1.5 
mg/kg/d). Following 20-da of treatment, tumors were harvested and 
analyzed by Western Blot for pJNK, JNK, phospho-86 ribosomal pro-
tein, and 86 ribosomal protein. (B) LS174T were stably transfected 
with a plasmid encoding a dominant negative mutant of JNK or 
with pcDNA3. Cells were subsequently injected into the flank of 
nude mice, and mi ce were either treated with vehicle or with rapan1y-
cin (1.5 mg/kg/d, intraperitoneally) for 20 d (n = 5/group). Points: av-
erage value of tumor volume. Bars: SD. *P < 0.05 compared with 
pcDNA3 or as speci:fied by brackets (one-way ANOVA). 
paradigm, the use of rapamycin as single agent in var-
ious clinical studies was associated with sporadic re-
sponses and combined therapy has potentiated the 
anticancer efficacy of rapamycin [ 4, 5]. Indeed, combin-
ing treatment that target the epidermal growth factor 
receptor, FOXOl, MEK, or DNAmethyltransferase po-
tentiated the anticancer efficacy ofrapamycin [20-23]. 
We further show here that combining JNK and mTOR 
inhibitors have additive antiproliferative effect on 
1817 4T cells. Indeed, simultaneous inhibition of JNK 
and mTOR in 18174T resulted in reduced tumor 
growth both in vitro and in vivo that was superior to 
single inhibition (Fig. 2B, SB, and 4B). Therefore, com-
bining JNK and mTOR inhibitors may provide a navel 
strategy in cancer therapy. 
The strategy to combine rapamycin with other signal-
ing pathway inhibitors relies also on a biological ratio-
nale. In fact, the inhibition of mTORCl by mpamycin 
stops a negative feedback loop whereby 861{1 signals 
back to PI3K [6]. This results in the activation ofprolif-
erative and prosurvival signals, includingthePI3K/Akt 
and the RAS/RAF/MEK/Erksignalingpathways, which 
counteract the antîcancer efficacy of rapamycin. Simi-
larly, we have found in 1817 4T cells that rapamycin in-
duces the activation of Akt, suggesting the removal of 
a negative feedback loop. Our data further show that 
rapamycin leads to the phosphorylation and activation 
of JNK signaling pathway. Consistent with this finding, 
it has been reported that rapamycin activates JNK in 
a human glioblastoma cell line that exp1·esses a consti-
tutively active mutant of the epidermal growth factor 
receptor [24]. Furthermore, rapamycin also increased 
JNK phosphorylation in MIN6 cells and Wistar rat pan-
creatic ilets [25]. Finally rapamycin was also shown to 
induce a transient activation of JNK in cells expressing 
wild-type p53 and a sustained activation in cells ex-
pressing mutant p53 [26]. 
One mechanism regulating rapamycin-mediated 
JNK activation involves the apoptosis signal-
regulating kinase 1 (ASKl). Under serum-free condi-
tions, rapamycin activates ASKl by inhibiting protein 
phosphatase 5 [27]. In turn, the activation of ASKl 
leads to the up-regulation of JNK signaling pathway. 
Interestingly, ASKl mediated JNK activation depends 
on the expression of 4E-BP1, a downstream effector of 
mTOR, and not of S6Kl. This suggests that rapamycin 
activates JNK independently of the S6Kl/PI3K feed-
back loop. In this study, we have not found any change 
in the phosphorylation status of ASK-1 following 
rapamycin treatment, suggesting that another mecha-
nism regulates rapamycin-mediated JNK activation 
in 1S174T cells (data not shown). Furthermore, 
rapamycin-mediated ASKl/JNK activation induces 
cell apoptosis which was not observed in 1817 4T cells. 
Since rapamycin increases PI3K activity in L8174T 
cells and since JNK is a functional downstream target 
of PI3K, we initially hypothesized that rapamycin-
mediated JNK activation was PI3K-dependent [16]. 
However, the use of LY294002, a PI3K inhibitor, failed 
to block rapamycin-mediated JNK phosphorylation 
(data not shown). Therefore, further studies are needed 
to describe the mechanism by which rapamycin-
induces JNK phosphorylation in 1817 4T cells. 
Our study shows that rapamycin-induced JNK acti-
vation was detrimental to the antîcancer efficacy of ra-
pamycin, pxoviding an experimental evidence to 
combine JNK and mTOR inhibitors. However, one 
may speculate that blocking JNK would potentiate 
the effectiveness of rapamycin regardless of whether 
rapamycin induces JNK activation or not. In fact, we 
found that JNK and mTOR inhibitors had also additive 
antiproliferative effects in HT29 cells in which rapamy-
cin did not induce JNK activation (data not shown). 
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Therefore, the strategy of combining mTOR and JNK 
inhibitors may not be restricted to cancer cells in which 
rapamycin activa tes JNK Thus, to apply these findings 
to a clinical setting, it will be important to identify bio-
Jllal'kers for cancer cells that are likely to respond to 
combined mTOR and JNK inhibition rather than iden-
tify cells in which rnpamycin induces JNK activation. 
Emerging evidences show that JNK is implicated in 
oncogenic transformation, particularly in the intestine. 
Indeed, in a mouse model of intestinal tumorigenesis, 
the number of tumor was reduced by the ablation of 
c-Jun or the mutation of JNK phosphorylation sites 
on c-Jun, suggesting that JNK participates in the 
transformation process in the intestine [28]. Consistent 
with this, JNK also prnmotes colorectal carcinogenesis 
under high-fat dietary conditions [14]. Furthermore, 
high levels of JNK expression are found in colon cancer 
[29]. Our study further underlines the role of JNKin co-
lorectal cancer cell growth, as the inhibition of JNK in 
LSl 74T colon cancer cells reduced cell proliferation in 
vitro and tumor xenograft growth in vivo. Finally, since 
mTOR signaling pathway is also involved in colon can-
cer progression [30-32], our observation that the com-
bined JNK and mTOR inhibition had synergistic 
effects might be particularly relevant in the context of 
colon cancer. 
In conclusion, our study shows that the anticancer ef-
ficacy of rapamycin can be potentiated by the simulta-
neous inhibition of JNK signaling pathway, and may 
provide a novel strategy in cancer therapy. 
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